PubMed Health⌕ Search

Biomedical subjects

T Danao

Publications and source records attributed to T Danao.

7 recordsLinked to original sources
PubMed1992

Nitrogen mustard as induction therapy for rheumatoid arthritis: clinical and immunologic effects.

We treated 5 patients diagnosed with rheumatoid arthritis (RA) with nitrogen mustard (HN2) and monitored clinical and immunologic variables. HN2, 0.3 mg/kg ideal body weight was given over 7 days. Disease activity and immune function were monitored during and after treatment. Duration of morning stiffness (p = 0.0044), joint count (p = 0.0140), and assessment of pain (p = 0.0264) and function (p = 0.0057) improved by Day 6. T lymphocytes (p = 0.0060), especially T memory cells (CD4CD29; p = 0.0017) fell dramatically. HN2 is effective for rapidly gaining control of active RA. This effect is T cell specific.

Aged↗
PubMed1992

Chronic fatigue syndrome.

Fatigue is one of the most common complaints among patients seen in the primary care setting. Chronic fatigue syndrome, which has recently been called chronic fatigue immune dysfunction syndrome, is distinctive, with an abrupt onset of symptoms that wax and wane for at least six months. Usually there is low-grade fever, pharyngitis and tender, but not enlarged, lymph nodes. The fatigue can be disabling and is often made worse by physical activity. Some patients with this disorder have also been found to have highly characteristic immunologic abnormalities. Treatment can be rewarding and is based on patient education and support, exercise and symptomatic therapies for abnormal sleep patterns, musculoskeletal pain and other symptoms.

Adolescent↗
PubMed1990

Pulsed suppressive treatment in rheumatoid arthritis: intravenous methylprednisolone and nitrogen mustard.

Persistent polyarticular rheumatoid arthritis (RA) and aggressive disease flares resistant to conventional therapy can effectively be controlled by intravenous pulse methylprednisolone (IVMP) or nitrogen mustard (HN2). The efficacy, toxicity and immunologic effects of each agent are reviewed. Clinical response is evident within days of the start of therapy for both; persisting up to 6 weeks for IVMP and at least 59 days for HN2. Morbidity from both agents is minimal when appropriate precautions are taken. No mortalities directly related to either modality have been reported in RA.

Arthritis, Rheumatoid↗
PubMed1989

The anticardiolipin syndrome.

Anticardiolipin antibodies delineate a recently defined syndrome characterized by venous and arterial thrombosis, thrombocytopenia and recurrent fetal loss, usually in the setting of autoimmune disease. A recently standardized enzyme immunoassay for this antibody is becoming widely available. Treatment is controversial and includes prednisone and aspirin in pregnant patients. Anticoagulation therapy has been recommended for thrombosis. The roles of plasmapheresis and cytotoxic agents have not yet been defined.

Abortion, Spontaneous↗
PubMedDate not supplied

Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases.

We report a retrospective study of 17 patients with systemic lupus erythematosus who were treated with oral methotrexate given as a mean weekly dose of 8.47 +/- 1.72 mg. Methotrexate treatment resulted in symptomatic improvement in 57% of patients and allowed the reduction of the mean daily dose of prednisone from 16.66 mg initially to 8.99 mg at one year follow-up. Twelve of 17 patients (70.6%) experienced at least one episode of toxicity. Factors which might be associated with toxicity are analyzed. Because of its potential as a corticosteroid-sparing agent, controlled studies of methotrexate for the treatment of systemic lupus erythematosus are indicated.

Adult↗
PubMedDate not supplied

Antibodies to the human T lymphocytotropic type I in systemic lupus erythematosus.

We tested sera from 94 patients with systemic lupus erythematosus (SLE) by Western immunoblot. Using the criteria established by the Public Health Service Working Group, 11 (12%) sera were reactive, 29 (31%) indeterminate and 54 (57%) unreactive. When the reactive sera were immunoblotted against an extract from an uninfected control lymphoblastoid cell line, identical bands were obtained. HTLVI antigenemia could not be detected in any of the reactive sera. This suggests that previously described "antibodies to HTLVI" in SLE represent artifactual reaction with cellular components in the antigenic extract.

Blotting, Western↗